Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,339 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,339 shares of the business’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the completion of the transaction, the insider now owns 140,375 shares of the company’s stock, valued at approximately $4,849,956.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Dyne Therapeutics Stock Up 6.0 %

Shares of DYN stock opened at $36.41 on Friday. The stock’s 50-day moving average price is $41.17 and its 200 day moving average price is $33.49. Dyne Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $47.45. The stock has a market capitalization of $3.18 billion, a PE ratio of -9.17 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.02. Analysts expect that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Institutional Trading of Dyne Therapeutics

Several hedge funds have recently made changes to their positions in DYN. RA Capital Management L.P. purchased a new position in shares of Dyne Therapeutics during the 1st quarter worth approximately $140,666,000. Vanguard Group Inc. raised its position in Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after acquiring an additional 1,110,629 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Dyne Therapeutics by 23,512.0% in the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after acquiring an additional 2,663,910 shares during the period. Artal Group S.A. boosted its position in shares of Dyne Therapeutics by 24.6% during the 1st quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock worth $43,095,000 after purchasing an additional 300,000 shares in the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Dyne Therapeutics by 10.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company’s stock worth $42,881,000 after purchasing an additional 114,888 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analysts Set New Price Targets

DYN has been the subject of a number of recent research reports. Oppenheimer reiterated an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Guggenheim lifted their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Stifel Nicolaus lifted their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. increased their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. Finally, Piper Sandler boosted their target price on Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.